SE0402198D0 - Method - Google Patents

Method

Info

Publication number
SE0402198D0
SE0402198D0 SE0402198A SE0402198A SE0402198D0 SE 0402198 D0 SE0402198 D0 SE 0402198D0 SE 0402198 A SE0402198 A SE 0402198A SE 0402198 A SE0402198 A SE 0402198A SE 0402198 D0 SE0402198 D0 SE 0402198D0
Authority
SE
Sweden
Prior art keywords
patient
haplotype
identifying
treatment
candidate
Prior art date
Application number
SE0402198A
Other languages
English (en)
Inventor
Helen Jean Ambrose
Mitchell Joel Goldman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0402198A priority Critical patent/SE0402198D0/sv
Publication of SE0402198D0 publication Critical patent/SE0402198D0/sv
Priority to US11/575,106 priority patent/US20080176224A1/en
Priority to CNA2005800388406A priority patent/CN101056994A/zh
Priority to PCT/SE2005/001317 priority patent/WO2006031181A1/en
Priority to EP05779030A priority patent/EP1789583A1/en
Priority to JP2007531132A priority patent/JP2008512114A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SE0402198A 2004-09-13 2004-09-13 Method SE0402198D0 (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE0402198A SE0402198D0 (sv) 2004-09-13 2004-09-13 Method
US11/575,106 US20080176224A1 (en) 2004-09-13 2005-09-12 Methods for Identifying a Patient as a Candidate for Treatment with a Long Acting Beta Agonist and for Predicting a Patient's Response to Long Acting Beta2 Agonist Therapy by Analysing Polymorphisms in the Beta2-Adrenergic Receptor Gene
CNA2005800388406A CN101056994A (zh) 2004-09-13 2005-09-12 将患者鉴定为用长效beta激动剂治疗的候选者并用于通过分析beta2肾上腺素能受体基因中的多态性来预测患者对长效beta2激动剂治疗的反应的方法
PCT/SE2005/001317 WO2006031181A1 (en) 2004-09-13 2005-09-12 Methods for identifying a patient as a candidate for treatment with a long acting beta agonist and for predicting a patient’s response to long acting beta2 agonist therapy by analysing polymorphisms in the beta2-adrenergic receptor gene
EP05779030A EP1789583A1 (en) 2004-09-13 2005-09-12 Methods for identifying a patient as a candidate for treatment with a long acting beta agonist and for predicting a patient's response to long acting beta 2 agonist therapy by analysing polymorphs ims in the beta 2 -adrenergic receptor gene
JP2007531132A JP2008512114A (ja) 2004-09-13 2005-09-12 長時間作用型ベータアゴニストでの処置用の候補者として患者を同定するためのおよびベータ２−アドレナリン受容体遺伝子の中の多型性を分析することにより長時間作用型ベータ２アゴニスト治療に対する患者の応答を予測するための方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0402198A SE0402198D0 (sv) 2004-09-13 2004-09-13 Method

Publications (1)

Publication Number Publication Date
SE0402198D0 true SE0402198D0 (sv) 2004-09-13

Family

ID=33157525

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0402198A SE0402198D0 (sv) 2004-09-13 2004-09-13 Method

Country Status (6)

Country Link
US (1) US20080176224A1 (sv)
EP (1) EP1789583A1 (sv)
JP (1) JP2008512114A (sv)
CN (1) CN101056994A (sv)
SE (1) SE0402198D0 (sv)
WO (1) WO2006031181A1 (sv)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2450444B1 (en) * 2006-11-30 2013-06-05 ARKRAY, Inc. Probe for analyzing a polymorphism in the beta2AR gene, reagent, and obesity gene analysis method
JP2015533131A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ２−アドレナリン受容体作動薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2510799A (en) * 1997-12-30 1999-08-09 Max-Delbruck-Centrum Fur Molekulare Medizin Novel sequence variants of the human beta2-adrenergic receptor gene and use thereof
DE60021718D1 (de) * 1999-03-12 2005-09-08 Univ Cincinnati Cincinnati Variationen in der arzneimittelantwort in zusammenhang mit polymorphismen des adrenergen rezeptors beta 2
AU2000243515A1 (en) * 2000-04-13 2001-10-30 Genaissance Pharmaceuticals, Inc. Association of beta2-adrenergic receptor haplotypes with drug response

Also Published As

Publication number Publication date
EP1789583A1 (en) 2007-05-30
JP2008512114A (ja) 2008-04-24
WO2006031181A8 (en) 2007-03-01
CN101056994A (zh) 2007-10-17
US20080176224A1 (en) 2008-07-24
WO2006031181A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2008070137A3 (en) Interferon alpha-induced pharmacodynamic markers
WO2007126758A3 (en) Method and system for determining whether a drug will be effective on a patient with a disease
MX2007006529A (es) Seleccionar pacientes para terapia con un inhibidor her.
WO2003060653A3 (en) Method and/or system for analyzing biological samples using a computer system
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
WO2009137015A3 (en) Biomarkers of ionizing radiation
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
EP1838867A4 (en) APOLIPOPROTEIN A-II ISOFORM USED AS BIOMARKER FOR PROSTATE CANCER
WO2008137838A3 (en) Interferon alpha-induced pharmacodynamic markers
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
EP3269815A3 (en) Method of treatment and screening method
EP2560002A3 (en) Method for isolating and/or identifying mesenchymal stem cells (MSC)
ATE406575T1 (de) Verfahren zur erkennung von medikamentenempfindlichkeit in patienten mit entzündungskrankheiten
NZ584642A (en) Factor involved in latent infection with herpesvirus, and use thereof
DE602006012995D1 (de) Brustkrebsdiagnoseverfahren
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
ATE412767T1 (de) Präbiotische effektanalyse
PL2057467T3 (pl) Sposób diagnozowania choroby z udziałem przeciwciała przeciwko receptorowi AT1
WO2005034737A3 (en) Methods for diagnosing and treating endoplasmic reticulum (er) stress diseases
SE0402198D0 (sv) Method
Amor et al. The impact of heavy smoking on male infertility and its correlation with the expression levels of the PTPRN2 and PGAM5 genes
EP1945105A4 (en) TAGGING AND RECOVERY OF DNA FROM ACCIDENTAL DROPS
ATE515576T1 (de) Protein c polymorphismen
WO2006006853A3 (en) Differences in intestinal gene expression profiles